VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2023 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
VYNE on Nasdaq
Shares outstanding
18,514,484
Price per share
$0.58
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
8,179,397
Total reported value
$4,743,526
% of total 13F portfolios
0%
Share change
+2,809,841
Value change
+$1,869,192
Number of holders
39
Price from insider filings
$0.58
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
CITADEL ADVISORS LLC 0% -103% $1,250 -$367,360 3,732 -100% Kenneth Griffin 30 Sep 2025

As of 31 Dec 2025, 39 institutional investors reported holding 8,179,397 shares of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE). This represents 44% of the company’s total 18,514,484 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) together control 44% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Shay Capital LLC 8.8% 1,624,349 +230% 0.15% $942,285
Anson Funds Management LP 6.9% 1,274,386 0.1% $739,271
Nantahala Capital Management, LLC 5.4% 1,000,000 0.03% $580,100
T3 Companies, LLC 5.1% 945,000 0% 0.7% $548,195
ACADIAN ASSET MANAGEMENT LLC 3.4% 638,492 +43% 0% $370,000
KVP Capital Advisors, LP 2.7% 500,551 0% 0.3% $290,370
VANGUARD GROUP INC 1.7% 314,545 +65% 0% $182,436
Ikarian Capital, LLC 1.4% 264,912 -8.7% 0.02% $153,675
ADAR1 Capital Management, LLC 1.4% 253,791 0.01% $147,224
GEODE CAPITAL MANAGEMENT, LLC 1.2% 225,152 +64% 0% $130,614
TWO SIGMA INVESTMENTS, LP 1.2% 220,000 -0.36% 0% $127,622
TWO SIGMA ADVISERS, LP 0.88% 163,100 +188% 0% $94,614
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.54% 100,341 +74% 0% $58,207
Rangeley Capital, LLC 0.54% 100,000 +100% 0.05% $58,010
BOOTHBAY FUND MANAGEMENT, LLC 0.44% 81,371 -24% 0% $47,203
XTX Topco Ltd 0.43% 79,040 0% $45,851
JANE STREET GROUP, LLC 0.39% 72,356 -51% 0% $41,974
UBS Group AG 0.34% 62,761 +1026% 0% $36,401
GSA CAPITAL PARTNERS LLP 0.29% 53,961 +50% 0% $31,000
BlackRock, Inc. 0.24% 44,404 0% 0% $25,759
CITADEL ADVISORS LLC 0.16% 30,526 0% $17,708
Virtu Financial LLC 0.14% 25,327 0% $15,000
FNY Investment Advisers, LLC 0.14% 25,000 0% $14,000
NORTHERN TRUST CORP 0.12% 23,110 0% 0% $13,406
COMMONWEALTH EQUITY SERVICES, LLC 0.1% 18,298 0% 0% $10,610

Institutional Holders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 8,179,397 $4,743,526 +$1,869,192 $0.58 39
2025 Q3 3,924,005 $1,315,944 -$9,032,746 $0.34 31
2025 Q2 8,048,768 $13,279,291 +$1,503,898 $1.65 44
2025 Q1 7,109,939 $11,401,092 -$2,382,241 $1.58 36
2024 Q4 7,028,274 $23,320,995 +$606,162 $3.35 34
2024 Q3 7,312,555 $14,256,902 -$1,226,342 $1.88 31
2024 Q2 7,942,286 $16,030,293 +$243,077 $1.97 30
2024 Q1 6,405,086 $19,663,149 +$378,435 $3.07 29
2023 Q4 7,863,834 $18,322,345 +$17,207,859 $2.33 32
2023 Q3 360,099 $1,445,870 -$33,734 $4.04 20
2023 Q2 375,960 $1,532,386 +$198,131 $4.10 19
2023 Q1 335,259 $1,031,948 +$1,031,948 $3.08 19